RecruitingPhase 1Phase 2NCT07046806

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)

Sponsor

Institute for Asthma and Allergy

Enrollment

10 participants

Start Date

Mar 10, 2025

Study Type

INTERVENTIONAL

Conditions

Hereditary Angioedema (HAE)Angioedema Bradykinin-mediated Angioedema C1 Inhibitor Deficiency

Summary

To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deucrictibant 20 mg capsule, a drug called Deucrictibant XR tablet, and others for people with angioedema, bradykinin-mediated angioedema, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDeucrictibant XR tablet

Deucrictibant 40 mg XR tablet for prophylaxis

DRUGPlacebo comparator to XR tablet

Placebo comparator to deucrictibant 40 mg XR tablet, prophylaxis

DRUGDeucrictibant 20 mg capsule

Deucrictibant active drug for on-demand treatment of angioedma attacks

DRUGPlacebo comparator to 20 mg capsule

Placebo comparator to Deucrictibant 20 mg capsule for on-demand treatment of angioedema attacks

Locations(1)

Institute For Asthma & Allergy

Wheaton, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07046806

Related Trials

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

NCT0725193324 locations

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

NCT0742849948 locations

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT0729844710 locations

A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

NCT072933641 location

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT0667988162 locations